Equillium, Inc. EQ
Set alert
At close · Oct 30
After hours · Oct 30, 6:42 PM ET
- YTD
- -11.61%
- 1 year
- -3.52%
- Open
- 1.38
- Prev close
- 1.42
- Mkt cap
- 107.36M
- Vol
- 310.72K
- Avg vol
- 581.01K
- EPS
- -0.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.29
- High
- 1.42
- Forward P/E
- -0.47
- Beta
- 1.83
- Short ratio
- 0.53
- Inst. own
- 20.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.8356
- 200-d avg
- 1.15
- 1y target
- 3.33
News
-
5 days ago benzinga.com
Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases
Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that the first subject has been dosed in…
5 days ago globenewswire.com
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of…
5 days ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…
-
2 weeks ago benzinga.com
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6
Leerink Partners analyst Will Soghikian assumes Equillium (NASDAQ:EQ) with a Outperform rating and announces Price Target of $6.
3 weeks ago globenewswire.com
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation New preclinical data further characterizes EQ504's…
3 weeks ago globenewswire.com
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation
1 month ago globenewswire.com
Equillium Announces Poster Presentations at the 7th International AHR Conference
New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation New preclinical data further characterize EQ504's effects on epithelial barrier repair and…
1 month ago defenseworld.net
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium (NASDAQ: EQ) Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for…
1 month ago marketbeat.com
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative…
1 month ago globenewswire.com
Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum
LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
1 month ago reuters.com
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed Elmet Group and Blue Moon Metals to restart the Springer tungsten project in Nevada.
1 month ago globenewswire.com
Equillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
2 months ago globenewswire.com
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations…
2 months ago defenseworld.net
Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Equillium, Inc. (NASDAQ: EQ - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports.…
-
3 months ago benzinga.com
Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ:EQ) with a Overweight rating and announces Price Target of $20.
4 months ago accessnewswire.com
EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake
Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June…
5 months ago globenewswire.com
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
5 months ago seekingalpha.com
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
5 months ago marketbeat.com
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and…
5 months ago globenewswire.com
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
-
5 months ago benzinga.com
Leerink Partners Upgrades Equillium to Outperform, Raises Price Target to $6
Leerink Partners analyst Thomas Smith upgrades Equillium (NASDAQ:EQ) from Market Perform to Outperform and raises the price target from $1 to $6.
5 months ago globenewswire.com
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
5 months ago benzinga.com
Equillium Q1 EPS $(0.06) Misses $(0.05) Estimate
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 75 percent increase over losses of $(0.24) per…
5 months ago globenewswire.com
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter
6 months ago globenewswire.com
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today…
6 months ago globenewswire.com
Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events
DealTrax Highlights Include: Powerful Tools & Streamlined Processes: Quick, efficient deal setup with digital capabilities Speed: Faster payment delivery to holders Seamless Delivery: Full-service…
-
6 months ago benzinga.com
B. Riley Securities Initiates Coverage On Equillium with Buy Rating, Announces Price Target of $6
B. Riley Securities analyst William Woods initiates coverage on Equillium (NASDAQ:EQ) with a Buy rating and announces Price Target of $6.
-
6 months ago benzinga.com
Raymond James Initiates Coverage On Equillium with Strong Buy Rating, Announces Price Target of $6
Raymond James analyst Martin Auster initiates coverage on Equillium (NASDAQ:EQ) with a Strong Buy rating and announces Price Target of $6.
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
6 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $10
Cantor Fitzgerald analyst Emma Nealon initiates coverage on Equillium (NASDAQ:EQ) with a Overweight rating and announces Price Target of $10.
-
7 months ago benzinga.com
Equillium Q4 EPS $(0.04) Beats $(0.14) Estimate
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.14) by 70.37 percent. This is a 75 percent increase over losses of $(0.16) per…
-
7 months ago benzinga.com
Roth Capital Initiates Coverage On Equillium with Buy Rating, Announces Price Target of $12
Roth Capital analyst Adam Walsh initiates coverage on Equillium (NASDAQ:EQ) with a Buy rating and announces Price Target of $12.
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
1 year ago benzinga.com
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session